Physician profile
David Schnaiderman
NPI 1982808572
$1,299.58
in general payments reported to CMS, 2019-2025
13 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $97.23 · 2021: $175 · 2022: $15.26 · 2023: $159 · 2024: $94.85 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $561 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.23 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $246.84 | 2023-2025 | Mounjaro, Trulicity |
| Abbvie INC. | $174.80 | 2021 | |
| Boston Scientific Corporation | $139.66 | 2025 | Axonics |
| Allergan, INC. | $139.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.91 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $102.30 | 2019 | |
| Intuitive Surgical, INC. | $97.23 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $94.85 | 2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $91.45 | 2019 | |
| Abiomed | $41.20 | 2025 | |
| Novartis Pharmaceuticals Corporation | $30.87 | 2022-2023 | |
| Phadia US INC. | $23.07 | 2025 | Immunocap |
| Amgen INC. | $13.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schnaiderman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.